Associated Papers
SATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma.
Brown C et al.
Cells, 2026
Exploring the role of splicing in TP53 variant pathogenicity through predictions and minigene assays.
Fortuno C et al.
Human Genomics, 2025
Genomic Characterization of Preclinical Prostate Cancer Cell Line Models.
Beatson EL et al.
International Journal of Molecular Sciences, 2024
Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling.
Macedo-Silva C et al.
Signal Transduction and Targeted Therapy, 2023
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.
Rosenberg S et al.
Molecular Oncology, 2023
Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer.
Zivanovic A et al.
Nar Cancer, 2023
Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis.
Ding D et al.
Nature Communications, 2023
Dual guide RNA-mediated concurrent C&G-to-T&A and A&T-to-G&C conversions using CRISPR base editors.
Zhao Y et al.
Computational and Structural Biotechnology Journal, 2023
Fanconi anemia pathway regulation by FANCI in prostate cancer.
Kaljunen H et al.
Frontiers in Oncology, 2023
Genomic landscape of lung cancer in the young.
Ruiz R et al.
Frontiers in Oncology, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability.
Reza MN et al.
Scientific Reports, 2021
Analysis and Interpretation of the Impact of Missense Variants in Cancer.
Petrosino M et al.
International Journal of Molecular Sciences, 2021
Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study.
Zhang H et al.
Oncology Letters, 2021
Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations-A Perspective from a Real-World Precision Medicine Cohort.
Rosenberg S et al.
Molecular Cancer Therapeutics, 2020
Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC.
Zhang Y et al.
Prostate Cancer and Prostatic Diseases, 2020
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer.
Kazantseva M et al.
Cell Death & Disease, 2019
From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion.
Quinn EA et al.
Cold Spring Harbor Molecular Case Studies, 2019
EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.
Zhao Y et al.
The Embo Journal, 2019
Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO et al.
Nature Genetics, 2018
Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells.
Chopra H et al.
Oncotarget, 2018
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A et al.
Cancer Discovery, 2015
Identifying the determinants of response to MDM2 inhibition.
Saiki AY et al.
Oncotarget, 2015
Reproducible Analysis of Post-Translational Modifications in Proteomes--Application to Human Mutations.
Holehouse AS et al.
Plos One, 2015
TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B et al.
Human Mutation, 2014
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.
Chappell WH et al.
Cell Cycle (georgetown, Tex.), 2012
Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
Kamada R et al.
The Journal of Biological Chemistry, 2011
Evaluation of transcriptional activity of p53 in individual living mammalian cells.
Imagawa T et al.
Analytical Biochemistry, 2009
Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53.
Prowald A et al.
The Prostate, 2007
A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.
Lehmann BD et al.
Cell Cycle (georgetown, Tex.), 2007
Parallel analysis of tetramerization domain mutants of the human p53 protein using PCR colonies.
Merritt J et al.
Genomic Medicine, 2007
Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L et al.
Human Mutation, 2006